HEC201625 / HEC Pharm - LARVOL DELTA

HEC201625, a novel oral small molecule inhibitor of PD-L1, demonstrated potent anti-tumor activities both in vitro and in vivo (AACR 2026) - "HEC201625 also demonstrated equivalent or superior efficacy to atezolizumab across multiple humanized immune system tumor models, including A375, NCI-H358, and MDA-MB-231... HEC201625 is a novel oral small molecule inhibitor of PD-L1 demonstrating potent and selective immune activation and favorable pharmacokinetics and preclinical safety profiles. These results support its further development as a clinical candidate, with IND-enabling studies ongoing and Phase I trials planned."

Preclinical • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor • KRAS